Michael Cecchini, MD
Research & Publications
Biography
News
Research Summary
Dr. Cecchini focuses on developing new treatments for patients living with advanced gastrointestinal cancers. His specific research includes leveraging innovating DNA damaging therapies as a strategy to enhance the immune response. He has participated as both a principal investigator or sub-investigator on more than 100 clinical trials. This includes cooperative group studies, industry studies, as well as investigator initiated clinical trials. He is also the national principal investigator for multiple studies. In addition to his clinical research, Dr. Cecchini collaborates with multiple laboratories to perform bench to bedside research to enhance treatment options for patients living with gastrointestinal cancers.
He currently receives research funding through his NIH K08 Career Development Award which is evaluating the relationship between DNA damage and the immune response for gastrointestinal cancers. He was also awarded a Young Investigator Award from the Conquer Cancer Foundation, during his fellowship.
Coauthors
Research Interests
DNA Repair; Gastrointestinal Neoplasms; Immunotherapy
Selected Publications
- Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas CancerMokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.
- 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancersHarding J, Hofheinz R, Fernandez M, Kuboki Y, Rasco D, Cecchini M, Shen L, Archuadze S, Geng J, Haderk F, Pant S. 371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers Annals Of Oncology 2022, 33: s706. DOI: 10.1016/j.annonc.2022.07.509.
- Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancerLi C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakih M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer Communications Medicine 2022, 2: 90. PMID: 35856081, PMCID: PMC9287310, DOI: 10.1038/s43856-022-00155-y.
- Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)Cecchini M, Chao J, Shyr Y, Cleary J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Hsu C, Stein S, Thumar J, Kortmansky J, Kunstman J, LoRusso P, Ivy P, Lacy J. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ) Cancer Research 2022, 82: ct170-ct170. DOI: 10.1158/1538-7445.am2022-ct170.
- Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Cecchini M, Sokol E, Vasan N, Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Journal Of Clinical Oncology 2022, 40: 3535-3535. DOI: 10.1200/jco.2022.40.16_suppl.3535.
- Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational StudyKalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, , Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study JMIR Cancer 2022, 8: e33859. PMID: 35588361, PMCID: PMC9164098, DOI: 10.2196/33859.
- Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMABeech C, Walther Z, Cecchini M, Gibson J. Tu1119: CLINICOPATHOLOGIC FEATURES AND MOLECULAR LANDSCAPE OF BRAF MUTATED MICROSATELLITE STABLE COLORECTAL CARCINOMA Gastroenterology 2022, 162: s-889-s-890. DOI: 10.1016/s0016-5085(22)62107-3.
- Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potentialGiner-Calabuig M, De Leon S, Wang J, Fehlmann TD, Ukaegbu C, Gibson J, Alustiza-Fernandez M, Pico MD, Alenda C, Herraiz M, Carrillo-Palau M, Salces I, Reyes J, Ortega SP, Obrador-Hevia A, Cecchini M, Syngal S, Stoffel E, Ellis NA, Sweasy J, Jover R, Llor X, Xicola RM. Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential British Journal Of Cancer 2022, 126: 1595-1603. PMID: 35197584, PMCID: PMC9130322, DOI: 10.1038/s41416-022-01754-1.
- A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers.Harding J, Hofheinz R, Elez E, Kuboki Y, Rasco D, Cecchini M, Shen L, Dowling E, Archuadze S, de Pereira B, Pant S. A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2022, 40: tps222-tps222. DOI: 10.1200/jco.2022.40.4_suppl.tps222.
- A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.Gabrail N, Tolcher A, Alese O, Cecchini M, Manish P, Park H, Berlin J, Hamilton E, Huang Y, Lu L, Wang J, Shi M, Tong M. A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2022, 40: tps375-tps375. DOI: 10.1200/jco.2022.40.4_suppl.tps375.
- Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital SystemPatel T, Miccio J, Cecchini M, Srikumar T, Stein S, Kortmanksy J, Johung K, Lacy J. Clinical outcomes of first line FOLFIRINOX vs . gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System Journal Of Gastrointestinal Oncology 2021, 0: 0-0. PMID: 35070386, DOI: 10.21037/jgo-21-202.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer.Peters GW, Wang S, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky JS, Stein S, Kunz PL, Lattanzi S, Park HSM, Boffa D, Johung KL, Jethwa KR. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: e68. PMID: 34701946, DOI: 10.1016/j.ijrobp.2021.07.422.
- Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal CancerPeters G, Wang S, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Kunz P, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-Operative Chemoradiotherapy With or Without Induction Chemotherapy for Operable Locally-Advanced Esophageal Cancer International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e68. DOI: 10.1016/j.ijrobp.2021.07.422.
- Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection?Guo Y, Czeyda-Pommersheim F, Miccio JA, Mahalingam S, Cecchini M, Pahade J. Can a simplified CT response criteria for vascular involvement in pancreatic adenocarcinoma after neoadjuvant therapy predict survival in patients who achieved subsequent R0 resection? Abdominal Radiology 2021, 46: 5609-5617. PMID: 34557934, DOI: 10.1007/s00261-021-03284-5.
- A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.Patel M, Naing A, Burris H, Lin C, Curigliano G, Thistlethwaite F, Minchom A, Ascierto P, De Braud F, Cecchini M, Hanekom W, Sainson R, Wilson R, Quaratino S. A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies. Journal Of Clinical Oncology 2021, 39: 2624-2624. DOI: 10.1200/jco.2021.39.15_suppl.2624.
- Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.Desai J, Fakih M, Pedersen K, Hong Y, Segal N, Allen S, Bailey L, Lenain C, Lu D, Sayyed P, Schulze J, Cecchini M. Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer. Journal Of Clinical Oncology 2021, 39: 82-82. DOI: 10.1200/jco.2021.39.3_suppl.82.
- Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients.Uhlig J, Stein S, Lacy J, Cecchini M, Kim K. Stage IV gastrointestinal stromal tumors: Epidemiology, treatment and outcomes in adult US patients. Journal Of Clinical Oncology 2021, 39: 462-462. DOI: 10.1200/jco.2021.39.3_suppl.462.